| Description | Imeglimin (EMD 387008) is an orally available antidiabetic compound that enhances mitochondrial function, enhances insulin secretion, promotes β-cell proliferation and improves pancreatic β-cell survival in mice. |
| In vitro | 在 Human endothelial cells (HMEC-1) 中，Imeglimin（100 μM 和 10 mM；100 μM 处理 24 小时，10 mM 处理 4 小时）能够预防细胞死亡[2]。 |
| In vivo | 在 4 周龄的雄性 C57BL/6JOlaHsd 小鼠中，口服 Imeglimin（200 mg/kg；每日 2 次；持续 6 周）引起了轻微的体重下降和食物摄入减少，并伴有一些腹泻，但这些现象仅在治疗的最初几天内观察到[1]。 |
| Synonyms | EMD 387008, EMD-387008, RVT-1501, PXL 008 |
| molecular weight | 155.2 |
| Molecular formula | C6H13N5 |
| CAS | 775351-65-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Soluble |
| References | 1. Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrialfunction in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64(6):2254-64. 2. Detaille D, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072. |